Abstract:Among the currently available commercial eye drops with cyclosporine A (Cs) there is a lack of long-acting dosage forms and products with a concentration of the drug substance higher than 0.1%, although Cs is widely used in ophthalmology. The aim of the research was to conduct the microscopic and biopharmaceutical evaluation of two formulations, an emulsion (EM) and a self-emulsifying oil (SEO), both with 0.5% of Cs, proposed for use in eye drops, and the comparison of both. SEO eye drops with Cs or any other drug substance are currently not available as marketed products, and the highest concentration of Cs in the ocular emulsion is only 0.1%. The microscopic evaluation of the emulsion and the SEO after emulsification with water was carried out using a high-resolution digital microscopy. The properties of both preparations were compared using the high dynamic range function or optical shadow effect mode. Images in the 3D composition mode were also recorded. The in vivo study of the Cs formulations was performed on male albino rabbits. The eye tolerance of the preparations was assessed using the ocular irritation test, which is a modified Draize test. Placebo carriers (without the drug substance) were also subjected to irritation testing. The concentration of Cs in the tissues (cornea and conjunctiva) and fluids (tear fluid and aqueous humor) of the rabbit eye was determined after multiple instillations of Cs-EM or Cs-SEO. The tested preparations were compared using the digital microscopy technique, which highlights the features of the formulations and eliminates the risk of unnoticeable properties that are difficult to observe in classical optical microscopy. Both tested Cs-loaded formulations are classified as practically non-irritating. There were also no significant differences when testing the placebo carriers. After a topical administration, Cs was widely distributed in all tissues (e.g., in cornea 1.3 ng/mg and 1.0 ng/mg) and fluids of the eye (e.g., in tear fluid 11.6 µg/mL and 4.3 µg/mL), after the administration of Cs-SEO and Cs-EM, respectively. The obtained results allow us to recognize both tested formulations, the emulsion and the self-emulsifying oil with 0.5% Cs content, as carriers safe for ophthalmic use and effective in delivering the drug substance to the structures of the eye.

Impact of Vehicle Physicochemical Properties on Modeling-Based Predictions of Cyclosporine Ophthalmic Emulsion Bioavailability and Tear Film Breakup Time

Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial

Cyclosporine release and distribution in ophthalmic emulsions determined by pulsatile microdialysis

Comparative study of cyclosporine A liposomes and emulsions for ophthalmic drug delivery: Process optimization through response surface methodology (RSM) and biocompatibility evaluation

Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations

Computational Model of In Vivo Corneal Pharmacokinetics and Pharmacodynamics of Topically Administered Ophthalmic Drug Products

Cyclosporine-loaded micelles for ocular delivery: Investigating the penetration mechanisms

Analytical considerations for measuring the globule size distribution of cyclosporine ophthalmic emulsions

Formulation and Evaluation of Cyclosporin A Emulgel for Ocular Delivery

Stability, safety, and transcorneal mechanistic studies of ophthalmic lyophilized cyclosporine-loaded polymeric micelles.

Population Pharmacokinetic Modeling of Azithromycin Eyedrops in Tears Following Single-Dose Topical Administration in Healthy Volunteers

Novel Microemulsion in Situ Electrolyte-Triggered Gelling System for Ophthalmic Delivery of Lipophilic Cyclosporine A: in Vitro and in Vivo Results

Improving the Topical Ocular Pharmacokinetics of Lyophilized Cyclosporine A-loaded Micelles: Formulation, in Vitro and in Vivo Studies

Role of micelle dynamics in enhancing cyclosporine uptake in hyaluronic acid-contact lenses for improved critical lens properties in dry eye management

A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.

Microscopic and Biopharmaceutical Evaluation of Emulsion and Self-Emulsifying Oil with Cyclosporine

Ocular Delivery of Cyclosporine A Based on Glyceryl Monooleate/poloxamer 407 Liquid Crystalline Nanoparticles: Preparation, Characterization,in Vitrocorneal Penetration and Ocular Irritation

Preparation and in Vitro Characterizations of Cyclosporine A Ocular Nanostructured Lipid Carriers

A Physiology-Based Mathematical Model to Understand Drug Delivery from Contact Lenses to the Back of the Eye

Thiolated Nanostructured Lipid Carriers As a Potential Ocular Drug Delivery System for Cyclosporine A: Improving in Vivo Ocular Distribution.

Studies on cationic ocular emulsions containing bipartitioned oil droplets to codeliver cyclosporin A and etodolac